The Technical AnalystExchange: SIX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Cassiopea SpA Price, Forecast, Insider, Ratings, Fundamentals & Signals
9.85% CHF35.70
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-03-04 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/19 | 2/19 | 4/19 | 1/20 | 2/20 | 2/21 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | ||
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -28.13 | sector: PE 25.29 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.65x |
| Company: PE -28.13 | industry: PE 17.08 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
CHF 0 - 0 ( +/- 0.00%) |
| ATR Model: 14 days |
SKIN.SW
Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy. As of December 2, 2021, Cassiopea S.p.A. operates as a subsidiary of Cosmo Pharmaceuticals N.V.